Welcome to our dedicated page for ILLUMINA SEC filings (Ticker: ILMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Illumina SEC filings document the company’s genomics technology business, financial results, governance and capital actions. Form 8-K reports cover quarterly and annual operating results, preliminary financial updates, share repurchase authorization, management and board changes, and Regulation FD disclosures.
The filing record also includes definitive proxy materials for annual meeting matters, director elections, compensation and shareholder voting. Material-event filings document completed acquisition activity, including the purchase of SomaLogic and Sengenics aptamer-based and functional proteomics assets, along with exhibits, common-stock repurchase disclosures and other capital-structure records.
Illumina (ILMN) reported an insider trade by its Chief Legal Officer. On 11/12/2025, the officer disposed of 323 shares of common stock at $122.79 per share. Following the transaction, the officer beneficially owned 18,210 shares, held directly.
Illumina, Inc. entered an underwriting agreement to issue and sell $500,000,000 aggregate principal amount of 4.750% notes due 2030. The offering is expected to close on November 25, 2025, subject to customary closing conditions.
Illumina expects to use the net proceeds for general corporate purposes, which may include repayment of its 5.800% notes due December 12, 2025 and completing the proposed acquisition of SomaLogic, Inc., including related fees and expenses. The notes will be issued off Illumina’s Form S‑3 shelf (No. 333-281921).
Illumina, Inc. is offering $500,000,000 aggregate principal amount of senior unsecured 4.750% notes due December 12, 2030. The notes pay interest semiannually on June 12 and December 12, beginning June 12, 2026, and are issued in $2,000 minimum denominations. They were priced at 99.962% with a 0.600% underwriting discount, resulting in gross proceeds of $496,810,000; estimated net proceeds are approximately $494,829,000.
Illumina intends to use the proceeds for general corporate purposes, which may include repaying its 5.800% notes due December 12, 2025 ($500 million outstanding as of September 28, 2025) and completing the proposed SomaLogic acquisition. The notes are unsecured and unsubordinated, ranking equally with Illumina’s other unsecured debt. They may be redeemed at Illumina’s option (make‑whole prior to the Par Call Date of November 12, 2030; at par thereafter), and include a change‑of‑control triggering event repurchase at 101% plus accrued interest.
The notes will not be listed; settlement is expected on or about November 25, 2025 (T+10). As context, Illumina reported $2.0 billion of debt and subsidiaries’ liabilities of approximately $818.0 million as of September 28, 2025.
Illumina, Inc. launched a preliminary prospectus supplement for a primary offering of senior unsecured notes. The Notes will pay interest semiannually and rank equally with Illumina’s existing unsecured debt, without subsidiary guarantees. They feature an issuer make-whole call prior to a defined par call date and are redeemable at 100% of principal on or after that date. If a change of control triggering event occurs, holders may put the Notes at 101% of principal plus accrued interest.
The company does not intend to list the Notes, and settlement is expected on a T+10 basis in book-entry form with minimum denominations of $2,000. Illumina states intended uses of proceeds include general corporate purposes, which may encompass repaying its 5.800% notes due December 12, 2025, of which $500.0 million was outstanding as of September 28, 2025, and funding the proposed acquisition of SomaLogic, including related fees and expenses.
As context, the Notes will be structurally subordinated to liabilities of subsidiaries and effectively subordinated to any future secured debt. Risk factors highlight limited covenants, potential rating changes, interest rate sensitivity that could affect trading prices, and the possibility that optional redemption could occur when rates are low.
Illumina (ILMN) reported an insider transaction on a Form 4 by its Chief Legal Officer, Scott M. Davies. On 11/05/2025, a transaction in 398 shares of common stock was recorded at $122.44 per share under transaction code F. Following this activity, Davies directly owned 18,533 shares of Illumina common stock.
Illumina, Inc. (ILMN) reported an insider transaction by its VP, Chief Accounting Officer.
On 11/05/2025, 206 shares of common stock were disposed of at $122.44 under transaction code F. After this transaction, the reporting person beneficially owns 13,486 shares, held directly.
Illumina (ILMN) insider transaction: The company’s SVP, Chief People Officer reported a Form 4 transaction on 11/05/2025. The filing shows a Code F entry for Common Stock with 296 shares disposed at $122.44 per share. Following this transaction, the officer beneficially owns 19,391 shares, held directly.
Illumina, Inc. (ILMN) insider transaction reported. An officer (Chief of Global Operations) filed a Form 4 for a transaction on 11/05/2025. The filing reports the disposition of 599 shares of common stock at $122.44 per share with transaction code F.
Following the reported transaction, the insider beneficially owned 22,476 shares, held directly. The filing was made by one reporting person.
Illumina, Inc. (ILMN) filed a Form 4 reporting an insider transaction by SVP & Chief Technology Officer Steven Barnard. The filing lists a 11/05/2025 transaction in which 515 shares of common stock were disposed of, coded “F,” at a price of $122.44 per share. After this transaction, Barnard directly beneficially owned 33,031 shares.
Illumina (ILMN) reported an insider purchase on Form 4. Director Scott Gottlieb bought 500 shares of common stock on 11/03/2025 at $122.13 per share, raising his direct holdings to 12,523 shares. The filing indicates it was submitted by an authorized signatory on 11/05/2025.